Category Archives: Healthcare

Chinese medical device and healthcare market-an analysis.

Summary

A comprehensive research report created through extensive primary research (inputs from industry experts, companies, stakeholders) and secondary research, the report aims to present the analysis of Global LNG Carrier Containment Market. The Global LNG Carrier Containment market has been analyzed by Carrier Type (Moss Type, Membrane Type), By Propulsion Type (Steam Reheat, ME-GI, DFDE, SSD Steam, TFDE, XDF, Others), By Capacity (30,000-124,999cm, 125,000-149,999cm, 150,000-180,000cm, >180,000cm). The Global LNG Carrier Containment market has been analyzed by Region (Americas, Europe, APAC, ROW) and by Country (United States, Bermuda, Greece, Norway, United Kingdom, China, Japan, Malaysia, South Korea, Qatar) for the historical period of 2014-2018 and the forecast period of 2019-2024.

LATEST CHINESE GUIDEBOOK FOR MEDICAL DEVICE 2019

China is one of the fastest growing global economies with a one-fifth population in the world. Nowadays, China has become the world’s second largest healthcare market after the United States. Along with sustained economic and population growth, and rapid population aging, the Chinese healthcare market has maintained an annual compound growth rate above 16 % since the 2010s. The statistical data showed that the scale of the Chinese healthcare market has reached RMB 6464.1 billion (about equivalent to US$973.5 billion) by 2017. Among them, the total value of medical device sales was RMB 663.2 billion (US$95.2 billion) with the annual compound growth rate of 20.27% by 2017. Medical devices have been widely used in the process of disease prevention, diagnosis, therapy, care, and rehabilitation.

However, large and medium-sized medical devices, high-end medical equipment and high-value medical materials are mainly relying on imported, such as the high-tech and high-valued imaging systems and navigation and positioning systems. Facing a gigantic population and rapid population aging, the Chinese government, on one side, accelerated the priority approval of innovative medical devices and relaxed the market access for overseas medical devices, on another side, intensified the supervision and administration for medical devices at the post—marketed. In recent years, China’s fast-track approval time is much shorter than any other country, which attracts more and more overseas medical device manufacturers to enter the Chinese healthcare market. Undoubtedly the Chinese healthcare market of nearly 1.4 billion populations is the huge business opportunities for the overseas medical device manufacturers.

At the same time, the Chinese regulatory authorities are changing regulatory framework to intensify the supervision and administration. The Chinese “State Administration for Market Regulation” and the “National Health Commission” jointly issued the latest version of “Measures for Medical Device Adverse Event Monitoring and Re-evaluation” in August 2018, which has been implemented on January 1, 2019. This is a challenge to overseas medical device manufacturers. To capture the huge business opportunities of the Chinese healthcare market and seize a larger part of the Chinese healthcare market, how do the foreign medical device manufacturers in compliance with the latest Chinese regulations on medical devices? How do the overseas medical device manufacturers operate business smoothly in China? Most importantly, overseas and multinational medical device manufacturers should always stand ready to respond to further regulation and policy changes occurred in China.

The overseas and multinational medical device manufacturers and their senior executive officers engaging in regulatory affairs need a thorough knowledge of the Chinese regulations for medical device adverse event reporting, monitoring and re-evaluation. China’s regulatory approach and culture are unique.

Latest Chinese Guidebook for Medical Device Adverse Events Reporting, Monitoring and Re-Evaluation (2019 Edition) is an essential resource for overseas and multinational medical device manufacturers to handle the medical device adverse event reporting, monitoring and re-evaluation smoothly in China, which provided a detailed guidance of comprehensive and thorough knowledge of the Chinese medical device adverse event reporting, monitoring and re-evaluation regulations.

Reasons to Buy

The Chinese “State Administration for Market Regulation” and the “National Health Commission” jointly issued the latest version of “Measures for Medical Device Adverse Event Monitoring and Re-evaluation” in August 2018, which has been implemented on January 1, 2019.

This is a challenge for overseas medical device manufacturers. To capture the huge business opportunities of the Chinese healthcare market and seize a larger part of the Chinese healthcare market, how do the foreign medical device manufacturers in compliance with the latest Chinese regulations on medical devices? How do the overseas medical device manufacturers operate business smoothly in China? Most importantly, overseas and multinational medical device manufacturers should always stand ready to respond to further regulation and policy changes occurred in China. The overseas and multinational medical device manufacturers and their senior executive officers engaging in regulatory affairs need a thorough knowledge of the Chinese regulations for medical device adverse event reporting, monitoring and re-evaluation. China’s regulatory approach and culture are unique.

Latest Chinese Guidebook for Medical Device Adverse Events Reporting, Monitoring and Re-Evaluation (2019 Edition) is an essential resource for overseas and multinational medical device manufacturers to handle the medical device adverse event reporting, monitoring and re-evaluation smoothly in China, which provided a detailed guidance of comprehensive and thorough knowledge of the Chinese medical device adverse event reporting, monitoring and re-evaluation regulations.

 Report Highlights

A brief description for China’s healthcare market landscape and rapidly changing regulatory framework that let the overseas and multinational medical device manufacturers clearly understand the present-day realities of the Chinese healthcare market landscape and rapidly changing regulatory framework, and tell the overseas and multinational medical device manufacturers the opportunities and challenges.

The Chinese regulatory authorities at various administrative levels and their respective functions and the Chinese huge medical device adverse event monitoring information network.

The detailed Chinese regulations for the marketing authorization holders’ duties and obligations that are important for the overseas and multinational medical device manufacturers and the agents within the territory of China designated by the overseas medical device manufacturers, because they must fulfill these duties and obligations that are stipulated by the Chinese regulatory authorities.

The detailed Chinese regulations for the medical device distributors’ and medical device user facilities’ duties and obligations that are important for the distributors within the territory of China designated by the overseas and multinational manufacturers exporting medical device products to China, because they must also fulfill their duties and obligations that are stipulated by the Chinese regulatory authorities.

The detailed Chinese regulations for the medical device adverse event reporting and evaluation, from the basic requirements, the different types of medical device adverse event reporting, and the time limitations for different types of medical device adverse event reporting to an entire process of medical device adverse event reporting to smoothly navigate complex regulatory requirements step by step, which is important for the overseas and multinational manufacturers of imported medical devices and the agents within the territory of China designated by the overseas medical device manufacturers, because they must be in compliance with these regulations.

The detailed description of how Chinese regulatory authorities implement the key monitoring on certain medical devices.

The detailed guidelines for the marketing authorization holders of the overseas and multinational medical device manufacturers exporting medical device products to China, they should adopt what risk control measures under what circumstances and report to the drug regulatory authorities to smoothly navigate complex regulatory requirements step by step.

The detailed guidelines for the marketing authorization holders of the overseas and multinational medical device manufacturers exporting medical device products to China, they should proactively conduct the re-evaluation under what circumstances and report to the drug regulatory authorities to smoothly navigate complex regulatory requirements step by step.

The detailed introduction for the Chinese regulatory authorities will carry out the focusing inspections on the marketing authorization holders under what circumstances.

An overview of a Chinese monitoring network for medical device adverse event reporting and monitoring, which covers the detailed regulatory authorities at various administrative levels and their functions, and the complete picture of Chinese monitoring network for medical device adverse event reporting and monitoring to provide a direction of gateway for medical device adverse event reporting and monitoring.

Category: Healthcare Market Research Reports

Contact Details:

Aarkstore Enterprise

Phone: +91 998 729 5242 | contact@aarkstore.com

Advertisements

Full-Digital Ultrasonic Diagnostic Apparatus Industry Overview – Market Research Report 2019

Full-Digital Ultrasonic

Aarkstore Enterprise culminates the newest Market Research Report “Global Full-Digital Ultrasonic Diagnostic Apparatus”

Full-Digital Ultrasonic Diagnostic Apparatus Report by Material, Application, and Geography Global Forecast to 2023 is a professional and in-depth research report on the worlds major regional market conditions, focusing on the main regions (North America, Europe and Asia-Pacific) and the main countries (United States, Germany, united Kingdom, Japan, South Korea and China).

The report firstly introducedthe Full-Digital Ultrasonic Diagnostic Apparatus basics: definitions, classifications, applications and market overview; product specifications; manufacturing processes; cost structures, raw materials and so on. Then it analyzed the worlds main region market conditions, including the product price, profit, capacity, production, supply, demand and market growth rate and forecast etc. In the end, the report introduced new project SWOT analysis, investment feasibility analysis, and investment return analysis.

The report includes six parts, dealing with:

1.) Basic Information;
2.) Asia Full-Digital Ultrasonic Diagnostic Apparatus Market;
3.) North American Full-Digital Ultrasonic Diagnostic Apparatus Market;
4.) European Full-Digital Ultrasonic Diagnostic Apparatus Market;
5.) Market Entry and Investment Feasibility;
6.) Report Conclusion.

For more inquiry contact our sales team at contact@aarkstore.com

Related Reports:

Global Multiscan Ultrasonic Diagnostic Equipment Market Research Report 2017

Asia Pacific Clinical Diagnostics Assays Market Report (2014-2024) – Market Size, Share, Price, Trend and Forecast

North America Clinical Diagnostics Assays Market Report (2014-2024) – Market Size, Share, Price, Trend and Forecast

Global Clinical Diagnostics Assays Market Report 2019 – Market Size, Share, Price, Trend and Forecast

Contact Details:

Aarkstore Enterprise
Phone: +91 – 22 2756 4963
24/7 Online Support: +91 9987295242
Email: enquiry@aarkstore.com
Our website: https://www.aarkstore.com
Our blog: https://www.aarkstore.com/blog
Follow us on LinkedIn – https://www.linkedin.com/company/aarkstore-enterprise/

Market for CAR-T Cell Therapy

Cell Therapy

Aarkstore Enterprise culminates the newest Market Research Report “Global CAR-T Cell Therapy Market – Market Size, Forecasts, Trials & Trends

EXECUTIVE SUMMARY

CAR-T cell therapy is a remarkably promising treatment for cancer patients. This emerging treatment represents one of the biggest breakthroughs since the introduction of chemotherapy.

In 2017, the world witnessed a historic CAR-T cell therapy approval when on August 30, 2017, Tisagenlecleucel (Kymriah) was approved by U.S. FDA for the treatment of children and young adults with acute lymphoblastic leukemia (ALL). On May 1, 2018, FDA approved Kymriah for a second indication (diffuse large B-cell lymphoma). By October 18, 2017, the FDA granted approval for Yescarta for treating patients with relapsed/refractory diffuse large B-cell lymphoma (r/rDLBCL) and other rare large B-cell lymphomas. Other notable approvals for CAR-T cell therapy products have also been achieved.

In August 2018, Kymriah and Yescarta secured approval in Europe, indicating the willingness of European regulators to usher in a new age of regenerative medicine. Novartis’ Kymriah was given marketing authorization in the EU for the treatment of blood cancers, including B-cell acute lymphoblastic leukaemia (ALL) and relapsed or refractory diffuse large B-cell lymphoma (DLBCL). Gilead/Kite Pharma’s Yescarta was authorized as a treatment for adult patients with relapsed or refractory DLBCL and primary mediastinal large B-cell lymphoma (PMBCL). Health Canada approved Kymriah as the first CAR-T therapy in Canada and the Therapeutic Goods Administration (TGA) approved it as the first CAR-T therapy in Australia.

What is CAR-T Cell Therapy?

Chimeric antigen receptors (CARs) are genetically engineered cells that are developed in the laboratory and infused into a patient to help in detecting and fighting cancer. The protein constructs stimulate anti-cancer T-cells, which in turn boost a patient’s immune system. CAR-T cell therapy is defined as a type of immunotherapy that teaches T cells to recognize and destroy cancer.
CAR-T is a type of immunotherapy where doctors collect immune cells, modify them in a laboratory, and provide them the power to easily recognize and kill cancer cells. When infused into a patient, the cells get multiplied and stay in the body as “living drugs.”

How Does CAR-T Cell Therapy Work?

T-cells form the backbone of CAR-T cell therapy. T-cells are the workhorses of our immune system and they play a key role in directing the immune response and killing cells infected by pathogens. In CAR-T cell therapy, blood is drawn from the patient and the T-cells are separated out. In the laboratory, a disarmed virus is used to genetically engineer the T-cells to produce chimeric antigen receptors (CARs) on their surface. These receptors are synthetic and do not exist naturally. Once infused into the patient, these CARs enable the T-cells recognize and get attached to an antigen (specific protein) on the tumor cell leading to the destruction of the tumor.

Like all cancer therapies, CAR-T cell therapy can also cause a number of side effects. However, all these side effects can be managed with standard supportive therapies including steroids. The widespread research activities, worldwide clinical trials and treatments in a limited number of U.S. hospitals have created a robust CAR T-cell market. This billion dollar market and projected growth would have been not possible without the remarkable efficacy of Kymriah and Yescarta in treating several types of blood cancers.

Market for CAR-T Cell Therapy

CAR-T cell therapy has swept the biotech industry by storm in recent years, creating hope that it could welcome in a new age of cancer treatment. However, the remarkable success stories have come from targeting CD19, which is now considered an antigen that holds the key to a limited range of blood cancers. Presently, this hematological arena is a highly competitive therapy space that is being shared between among leading CAR-T companies.

Scientists, investors and developers invariably agree that the key to longer-term success in this space depends on solving two major problems: identifying antigens other than CD19 that can be targeted with CAR-T therapy with strong efficacy and going beyond liquid cancers into solid tumor indications. CAR-T cell products to deal with solid tumors will undoubtedly offer a larger market potential.

However, it is not an easy task to identify the antigens found on the cells of solid tumors. There are reasons why CD19 is the most common target. It is seen solely on B cells, whose destruction via CAR-T therapy offers a straightforward route for treating B-cell leukemias and lymphomas. At the same time, loss of the body’s B cells is not particularly problematical, because their antibody-producing function can be reinstated by injecting intravenous immunoglobulin (IVIG) to patients.

Currently, the only two non-CD19-directed CAR-T therapies are those that target CD22 in B-cell malignancies and B-cell maturation antigen (BCMA) in multiple myeloma. CD22 is structurally analogous to CD19, while BCMA is an antigen expressed on plasma cells, whose functional loss can also be replaced with IVIG.

The problem with solid tumors is that there is little evidence of CAR-T being able to overcome the numerous difficulties that exist for these to be targeted efficiently. However, both academic and commercial groups are racing against time to identify the antigens on solid tumor cells and develop suitable CAR-T cells, because it represents large market potential.
There are several reasons which make solid tumors difficult to treat using CAR-T cell therapies. Globally, solid tumors outnumber the hematological tumors by 10 to one. In 2015, Novartis and PENN reported that their CART-meso failed to show any effect in patients with mesothelioma, ovarian cancer and pancreatic cancer. Moreover, there was very poor persistence of CAR-T cells in the patients.

The difficulty with solid tumors is that they are usually surrounded by a hostile, immuno-suppressive microenvironment. This environment presents many inhibitory factors that prevent CAR-T cells from reaching them. A typical CAR-T approach will not have success under these conditions. For this reason, Juno and Novartis are engaging in constructing CAR-T cells with novel designs that incorporate additional elements to boost activity within this setting. Currently, these products are in preclinical development.

Driving Forces for the CAR-T Therapy Market

With growing demand for CAR-T therapies, CAR-T companies are proliferating. Growing numbers of these companies are supported by:
• Increasing investment flowing into CAR-T cell research
• Landmark approvals of CAR-T cell therapies by the U.S. Food & Drug Administration (FDA) and the European Medicines Agency (EMA)
• Major acquisitions within the CAR-T industry
• Large IPOs within the CAR-T industry

As mentioned, 2017 was the first year that the U.S. FDA approved a CAR-T cell therapy, approving Kymriah in August 2017 and Yescarta in October 2017. Novartis produced Kymriah, a CAR-T therapy used to treat leukemia, while Gilead/Kite Pharma developed Yescarta, a CAR-T therapy for patients with lymphomas. Approvals for these products are now spreading globally, with authorizations permitted by the EU, Canada, and Australia, among others. The approval of these early CAR-T cell therapies has opened the gates for many other types of cell and gene therapies to claim respect, both from regulators, as well as from the broader scientific and medical communities.
CAR-T funding is also on the rise. At first the trend was subtle, but the tide swelled as CAR-T therapies like Kymriah and Yescarta reached the marketplace and created a CAR-T funding craze. CAR-T start-ups have been richly funded by investors eager to get into this trending area of regenerative medicine. Following IPOs by CAR-T players Kite Pharma, Bellicum, Juno Therapeutis and Cellectis totaling over $750 million, CAR-T developer Autolus announced a $150 million IPO.
This has bought the total value of recent CAR-T initial public offerings (IPO’s) to nearly $1 billion.

CAR-T Industry Deal-Making

The CAR-T industry has also witnessed aggressive deal-making in recent years. Celgene snagged Juno Therapeutics for a shocking $9 billion in January 2018 and Gilead acquired Kite Pharma for an astounding $11.9 billion in August 2017. After $20 billion of market capitalization from the CAR-T companies in 2018, the CAR-T market has continued to gain momentum.
There have also been more than a dozen CAR-T deals between pharmaceutical companies and academic institutions, with the best known being the partnership between Novartis and the University of Pennsylvania (UPenn). When Kymriah™ because the first CAR-T cell therapy to be approved in the U.S. in August 2017, it resulted from a 5-year collaboration between UPenn and Novartis.

CAR-T financing rounds have also proliferated. In one major example, Celularity raised $250 million in February 2018 to support development of placental-derived products, including T-cells that will be immune advantaged because of their derivation from the placenta. Celularity is looking to burst a major bottleneck in the industry by deriving T-cells from a single (allogeneic) cell line, potentially positioning itself to slash the price point for CAR-T treatments. In other significant example, London-based CAR-T start-up Allogene Therapeutics entered into an asset contribution deal with Pfizer in April 2018, as well as announced a $300 million Series A round.

To better understand and compete within the rapidly expanding CAR-T marketplace, claim this global strategic report to learn the identities and strategies of leading market competitors, access market size data accompanied by market segmentation and forecasts, review clinical trial activity within the sector, assess CAR-T market approvals by region, and importantly, evaluate industry deal-making, emerging technologies, and future directions for the industry at large.

For more inquiry contact our sales team at contact@aarkstore.com

Related Reports:

Contact Details:

Aarkstore Enterprise
Phone: +91 – 22 2756 4963
24/7 Online Support: +91 9987295242
Email: enquiry@aarkstore.com
Our website: https://www.aarkstore.com
Our blog: https://www.aarkstore.com/blog
Follow us on LinkedIn – https://www.linkedin.com/company/aarkstore-enterprise/

Global Animal Health Market Research Report , Growth and Forecast

animal health

Aarkstore Enterprise announced latest Market Research Report Titled “Global Animal Health Market

Executive Summary
A comprehensive research report created through extensive primary research (inputs from industry experts, companies, stakeholders) and secondary research, the report aims to present the analysis of Global Animal Health Market. The study on global animal health market has been analyzed By Type (Farm animal, Companion animal), By Product (Biologicals, Pharmaceuticals, Feed additives), By Route of drug administration (Oral, Parenteral, Topical, Transdermal) and By Distribution Channel (Retail, E-commerce, Veterinary Hospital, Clinic). The study on global animal health market has been analyzed By Region (North America, Europe, Asia Pacific, Rest of the world) and By Country (U.S, Canada, Germany, U.K, Italy, China, India and Mexico). The study assesses the animal health market for the historical period of 2013-2017 and the forecast period of 2018-2023.

According to the research report, “Global Animal Health Market: Analysis By Type (Farm, Companion), By Products (Biologicals, Pharmaceuticals, Feed Additives), By Route of drug administration (Oral, Parenteral, Topical, Transdermal), By Distribution Channel (Retail, E-commerce, Veterinary Hospital, Clinic), By Region, By Country: Opportunities and Forecast (2013-2023)”, the global animal health market is projected to display a high growth represented by a CAGR of 5.63% during 2018 – 2023.

Over the recent years, global animal health market has been witnessing growth, on account of several driving factors including increase in protein demand, increase in pet ownership rates, rising incidences of zoonotic disease and changing lifestyle of the people favouring individualism. Moreover heightening focus on food safety, increasing focus on animal welfare, growing scope in emerging markets and consolidation of the market is expected to propel the demand for animal health. In this research report, the market is segmented on the basis of type, product, route of drug administration as well as distribution channel. By type, farm animal is predicted to hold its dominant position in the market, but companion animals are growing at a faster rate. Amongst the regions, North America accounts for the largest regional share in the global animal health market in 2018. However, Asia Pacific is predicted to advance at the highest rate. Presence of vast consumer base, particularly in emerging nations such as China and India, in addition to growing per capita expenditure on pets is likely to drive the regional market.

The report titled “Global Animal Health Market: Analysis By Type (Farm, Companion), By Products (Biologicals, Pharmaceuticals, Feed Additives), By Route of drug administration (Oral, Parenteral, Topical, Transdermal), By Distribution Channel (Retail, E-commerce, Veterinary Hospital, Clinic), By Region, By Country: Opportunities and Forecast (2013-2023)” has covered and analyzed the potential of global animal health market and provides statistics and information on market size, shares and growth factors. The report intends to provide cutting-edge market intelligence and help decision makers take sound investment evaluation. Besides, the report also identifies and analyses the emerging trends along with major drivers, challenges and opportunities in the global animal health market. Additionally, the report also highlights market entry strategies for various companies across the globe.

Scope of the Report

Global Animal Health Market (Actual Period: 2013-2017, Forecast Period: 2018-2023)
• Animal Health Market – Size, Growth, Forecast
• By Type- Farm Animal, Companion Animal
• By Product – Biologicals, Pharmaceuticals, Feed additives
• By Route of Drug Administration- Oral, Parenteral, Topical and Transdermal
• By Distribution Channel – Retail, E-commerce, Veterinary Hospital and Clinic

Regional Market – North America, Europe, Asia-Pacific, Rest of the World (Actual Period: 2013-2017, Forecast Period: 2018-2023)
• Animal Health Market – Size, Growth, Forecast
• By Type- Farm Animal, Companion Animal
• By Product – Biologicals, Pharmaceuticals, Feed additives
• By Route of Drug Administration- Oral, Parenteral, Topical and Transdermal
• By Distribution Channel – Retail, E-commerce, Veterinary Hospital and Clinic

Country Analysis – U.S., Canada, Germany, U.K, Italy, India, China, Mexico (Actual Period: 2013-2017, Forecast Period: 2018-2023)
• Animal Health Market – Size, Growth, Forecast
• By Type- Farm Animal, Companion Animal
• By Product – Biologicals, Pharmaceuticals, Feed additives
• By Route of Drug Administration- Oral, Parenteral, Topical and Transdermal
• By Distribution Channel – Retail, E-commerce, Veterinary Hospital and Clinic

Other Report Highlights
• Market Dynamics – Drivers and Restraints
• Market Trends
• Competitive Analysis
• SWOT Analysis
• Porter Five Force Analysis
• Supply Chain Analysis
• Policy and Regulatory Landscape
• Company Analysis – Alivira Animal Health Limited, Boehringer Ingelheim, Zoetis, Elanco, Merck Animal Health, Chr. Hansen, Phibro Animal Health Corporation, ECO Animal Health, Bayer Animal Health, Dechra Pharmaceuticals.

For more inquiry contact our sales team at contact@aarkstore.com

Related Reports:

Contact Details:

Aarkstore Enterprise
Phone: +91 – 22 2756 4963
24/7 Online Support: +91 9987295242
Email: enquiry@aarkstore.com
Our website: https://www.aarkstore.com
Our blog: https://www.aarkstore.com/blog
Follow us on LinkedIn – https://www.linkedin.com/company/aarkstore-enterprise/

Development of US and Chinese Retail Giants in the Healthcare Sector | Aarkstore

Retail Healthcare Sector

Aarkstore Market Research published the new epoch of Market Research Report “Development Of US And Chinese Retail Giants In The Healthcare Sector

Since the end of 2017, several leading international retailers have conducted acquisitions and initiated investments in attempts to tap into the growing healthcare industry. The healthcare industry generally comprises of medical, pharmaceutical, and insurance components. This report provides an overview of acquisitions and investment plans of four retail giants: CVS Health, Walgreens, Amazon, and Alibaba in the healthcare space, outlines their existing healthcare landscape and advantages, and analyzes their strategies to drive their business in this arena.

  1. Development of retail brands in Healthcare sector
    1.1 Primary Healthcare Services Only
    1.2 Traditional Companies vs. Startups
    2. RetaiL brands Existing Healthcare Landscape
    3. Deployment strategies
    3.1 CVS Aims for Business Diversification by Integrating Medical, Pharmaceutical, and Insurance Services
    3.2 Walgreens Adds Telemedicine Services to Enhance Existing Medical Care Services
    3.3 Amazon Enters Medical Care Service for the First Time to Capture the Seniors Market
    3.4 Alibaba Aims to Deepen Presence in O2O Prescription Drug Services
    MIC Perspective
    Prescription Drugs and Medical Insurance are the Areas of Focus for Retail Giants
    Creating Service Differentiation is Key to Success
    Appendix
    Glossary of Terms
    List of Companies
    List of Tables
    Table 1 Overview of M&As of International Retail Giants
    Table 2 Self-operated Healthcare Service of Amazon and Walgreens
    Table 3 Retail Brands Deployment in the Healthcare Sector
    List of Figures
    Figure 1 Retail Giants Strategies for Healthcare Market Expansion

    List Of Tables

    Development of retail brands in the healthcare sector, touching on their main service types and the comparison between traditional companies and startups in this arena
    Retail brands existing healthcare landscape and includes their M&A activities in recent years
    Deployment strategies of leading retail brands such as CVS, Walgreen, Amazon, and Alibaba

    List Of Figures

    Figure 1 Retail Giants Strategies for Healthcare Market Expansion

For more inquiry contact our sales team at contact@aarkstore.com

Related Reports:

Contact Details:

Aarkstore Enterprise
Phone: +91 – 22 2756 4963
24/7 Online Support: +91 9987295242
Email: enquiry@aarkstore.com
Our website: https://www.aarkstore.com
Our blog: https://www.aarkstore.com/blog

Global Blood Plasma Market Opportunities and Forecast (2013-2023) | Aarkstore

Blood Plasma

Aarkstore Enterprise announced latest Market Research Report Titled “Global Blood Plasma Market Opportunities and Forecast (2013-2023)

Executive Summary

A comprehensive research report created through extensive primary research (inputs from industry experts, companies, stakeholders) and secondary research, the report aims to present the analysis Global Blood Plasma Market. The report analyses the Blood Plasma Market By Type (Immunoglobulins- IV+SC, Albumin, Factor VIII- Plasma Derived, and Others), By Region (North America, Europe, Asia Pacific, Rest of the World) and By Country (U.S, Canada, Germany, France, Italy, China, Japan, India, Australia, and South-East Asia). The report on Blood Plasma assesses the market for the actual period of 2013-2017 and the forecast period of 2018-2023.

According to the research report “Global Blood Plasma Market – Analysis By Type (Immunoglobulins – IV+SC, Albumin, Factor VIII – Plasma Derived), By Region, By Country (2018 Edition): Opportunities and Forecast (2013-2023)”, the global blood plasma market is projected to display a robust growth represented by a CAGR of 10.18% during 2018 – 2023.

The Blood Plasma market witness a substantial growth at a noteworthy rate over the past few years and anticipated to grow on the back of its increasing usage in plasma-derived medical products. In addition, rise in awareness towards plasma donation, rise of China blood plasma industry, introduction of new and specialized products, rising geriatric population, rapid increase of the healthcare expenditure on the diseases such as immunodeficiency, neurological disorders, clotting disabilities etc. anticipated to boost the market growth in future. Amongst the regions, North America accounts for the largest regional share in the global blood plasma market. Key factor driving the robust growth rate in North America region is collection of source plasma in large volume for the fractionation process.

The report titled “Global Blood Plasma Market – Analysis By Type (Immunoglobulins – IV+SC, Albumin, Factor VIII – Plasma Derived), By Region, By Country (2018 Edition): Opportunities and Forecast (2013-2023)” has covered and analysed the potential of Global Blood Plasma Market and provides statistics and information on market size, shares and growth factors. The report intends to provide cutting-edge market intelligence and help decision makers take sound investment evaluation. Besides, the report also identifies and analyses the emerging trends along with major drivers, challenges and opportunities in the global blood ingredients market. Additionally, the report also highlights market entry strategies for various companies across the globe.

Scope of the Report

Global Blood Plasma Market (Actual Period: 2013-2017, Forecast Period: 2018-2023)
• Blood Plasma Market – Size, Growth, Forecast
• Analysis By Type- Size, Volume, Growth, Forecast
o Immunoglobulin (IV+SC)
o Albumin
o Factor VIII (Plasma Derived)

Regional Markets – North America, Europe, Asia Pacific, and Rest of the World (Actual Period: 2013-2017, Forecast Period: 2018-2023)
• Blood Plasma Market – Size, Growth, Forecast
• Analysis By Type
o Immunoglobulin (IV+SC)
o Albumin
o Factor VIII (Plasma Derived)

Country Analysis – U.S., Canada, Germany, France, Italy, China, Japan, India, Australia, and South-East Asia. (Actual Period: 2013-2017, Forecast Period: 2018-2023)
• Blood Plasma Market – Size, Growth, Forecast
• Analysis By Type
o Immunoglobulin (IV+SC)
o Albumin
o Factor VIII (Plasma Derived)

Other Report Highlights
• Market Dynamics – Drivers and Restraints
• Market Trends
• Porter Five Forces Analysis
• Company Analysis – CSL Limited, Baxter International, Grifols S.A, Octa Pharma, Emergent Bio-solutions, Antaris Pharma, AMAG Pharma, Biota Pharma, Bio delivery Science International, Biotest A.G.

For more inquiry contact our sales team at contact@aarkstore.com

Related Reports:

Contact Details:

Aarkstore Enterprise
Phone: +91 – 22 2756 4963
24/7 Online Support: +91 9987295242
Email: enquiry@aarkstore.com
Our website: https://www.aarkstore.com
Our blog: https://www.aarkstore.com/blog

 

Pharmaceuticals and Healthcare – Autoimmune Drugs Markets in China

Autoimmune Drugs

Chinas demand for Autoimmune Drugs has grown at a fast pace in the past decade. In the next decade, both production and demand will continue to grow. The Chinese economy maintains a high speed growth which has been stimulated by the consecutive increases of industrial output, imports & exports, consumer consumption and capital investment for over two decades. This new study examines Chinas economic trends, investment environment, industry development, supply and demand, industry capacity, industry structure, marketing channels and major industry participants. Historical data (2007, 2012 and 2017) and long-term forecasts through 2022 and 2027 are presented. Major producers in China are profiled.

The primary and secondary research is done in China in order to access up-to-date government regulations, market information and industry data. Data were collected from the Chinese government publications, Chinese language newspapers and magazines, industry associations, local governments industry bureaus, industry publications, and our in-house databases. Interviews are conducted with Chinese industry experts, university professors, and producers in China. Economic models and quantitative methods are applied in this report to project market demand and industry trends. Metric system is used and values are presented in either Yuan (RMB, current price) and/or US dollars.

Our market research reports provide hard-to-find market data and analyses. Today, China has the largest market in the world. Tremendous fast-growing markets for imports and business opportunities for companies around the world. If you want to expand your business or sell your products in China, our research reports provide the insights and projections into Chinese markets necessary for you to do so.

For more inquiry contact our sales team at contact@aarkstore.com

Related Reports:

Autoimmune Drugs Companies in China

Global Autoimmune Disease Diagnosis Market Professional Survey Report 2018

Global Autoimmune Partnering 2012-2018: Deal trends, players and financials

Global Autoimmune Disorders Treatment Market Research Report 2016

Autoimmune Technologies, LLC Company Profile- Outlook, Business Segments, Competitors, Goods and Services, SWOT and Financial Analysis

 

Contact Details:

Aarkstore Enterprise
Phone: +91 – 22 2756 4963
24/7 Online Support: +91 9987295242
Email: enquiry@aarkstore.com
Our website: http://www.aarkstore.com
Our blog: http://www.aarkstore.com/blog

 

%d bloggers like this: